Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Assets (2021 - 2025)

Lyell Immunopharma (LYEL) has disclosed Return on Assets for 5 consecutive years, with 0.69% as the latest value for Q4 2025.

  • Quarterly Return on Assets fell 8.0% to 0.69% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.69% through Dec 2025, down 8.0% year-over-year, with the annual reading at 0.62% for FY2025, 8.0% down from the prior year.
  • Return on Assets hit 0.69% in Q4 2025 for Lyell Immunopharma, up from 0.83% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.17% in Q3 2021 to a low of 0.83% in Q2 2025.
  • Historically, Return on Assets has averaged 0.37% across 5 years, with a median of 0.26% in 2023.
  • Biggest five-year swings in Return on Assets: rose 2bps in 2023 and later crashed -53bps in 2025.
  • Year by year, Return on Assets stood at 0.18% in 2021, then decreased by -2bps to 0.19% in 2022, then tumbled by -54bps to 0.29% in 2023, then crashed by -108bps to 0.6% in 2024, then dropped by -14bps to 0.69% in 2025.
  • Business Quant data shows Return on Assets for LYEL at 0.69% in Q4 2025, 0.83% in Q3 2025, and 0.83% in Q2 2025.